Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects

Oncotarget

Volumn 5, Issue 11, 2014, Pages 3823-3835

  Chang, Yi Wen ^a,b,c   Su, Chih Ming ^d,e   Su, Yen Hao ^c,e   Ho, Yuan Soon ^d,f   Lai, Hui Huang ^c,g   Chen, Hsin An ^c,d,e   Kuo, Min Liang ^h   Hung, Wen Chun ^c   Chen, Ya Wen ^c   Wu, Chih Hsiung ^d,e   Chen, Pai Sheng ^g   Su, Jen Liang ^c,i,j,k  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^h NATIONAL TAIWAN UNIVERSITY   (Taiwan)

ⁱ CHINA MEDICAL UNIVERSITY   (Taiwan)

^j CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^k ASIA UNIVERSITY   (Taiwan)

more..

Author keywords

Drug resistance; Metastasis; VEGFR 3; VEGFR 3 targeting peptides

Indexed keywords

ANTINEOPLASTIC AGENT; CYSTEINYLASPARAGINYLASPARTYLSERYLHISTIDYLMETHIONYLLEUCYLHISTIDYLCYSTEINE; CYSTEINYLASPARAGINYLASPARTYLSERYLHISTIDYLMETHIONYLLYCYLLEUCYLCYSTEINE; CYSTEINYLASPARAGINYLTYROSYLSERYLHISTIDYLLEUCYLPHENYLALANYLTYROSYLCYSTEINE; CYSTEINYLLEUCYLTHREONYLSERYLSERYLLEUCYLARGINYLSERYLCYSTEINE; CYSTEINYLPROLYLARGINYLSERYLPROLYLSERYLLEUCYLGLUTAMYLCYSTEINE; CYSTEINYLPROLYLARGINYLSERYLPROLYLSERYLLEUCYLTHREONYLCYSTEINE; CYSTEINYLTYROSYLTYROSYLGLYCYLGLUTAMYLSERYLLYCYLTYROSYLCYSTEINE; CYSTEINYLTYROSYLTYROSYLTRYPTOPHYLGLUTAMYLSERYLLYCYLTYROSYLCYSTEINE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3; PEPTIDE; VEGFR3 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL MOTILITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; EMBRYO; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LUNG METASTASIS; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR INVASION; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DISEASE COURSE; DRUG RESISTANCE; GENETICS; HEK293 CELL LINE; LUNG NEOPLASMS; MCF 7 CELL LINE; METABOLISM; METASTASIS; PHOSPHORYLATION; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HEK293 CELLS; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MCF-7 CELLS; MICE; MICE, SCID; NEOPLASM METASTASIS; PEPTIDES; PHOSPHORYLATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84903547377     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1709     Document Type: Article

References (33)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine reviews. 2003; 24(4): 389-427.
2. Karpanen T and Alitalo K. Lymphatic vessels as targets of tumor therapy? The Journal of experimental medicine. 2001; 194(6):F37-42.
3. Wu Y, Zhong Z, Huber J, Bassi R, Finnerty B, Corcoran E, Li H, Navarro E, Balderes P, Jimenez X, Koo H, Mangalampalli VR, Ludwig DL, Tonra JR and Hicklin DJ. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(21):6573-6584.
4. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H and Sherman M. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24(5):769-777.
5. Plate K. From angiogenesis to lymphangiogenesis. Nature medicine. 2001; 7(2):151-152.
6. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K and Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature medicine. 2001; 7(2):192-198.
7. Gershenwald JE and Fidler IJ. Cancer. Targeting lymphatic metastasis. Science. 2002; 296(5574):1811-1812.
8. Witte D, Thomas A, Ali N, Carlson N and Younes M. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer research. 2002; 22(3):1463-1466.
9. Van Trappen PO, Steele D, Lowe DG, Baithun S, Beasley N, Thiele W, Weich H, Krishnan J, Shepherd JH, Pepper MS, Jackson DG, Sleeman JP and Jacobs IJ. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. The Journal of pathology. 2003; 201(4):544-554.
10. Dias S, Choy M, Alitalo K and Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood. 2002; 99(6): 2179-2184.
11. Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, Kuo IH, Chen HY, Hung MC and Kuo ML. The role of the VEGFC/VEGFR-3 axis in cancer progression. British journal of cancer. 2007; 96(4):541-545.
12. Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, Hung MC and Kuo ML. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer cell. 2006; 9(3):209-223.
13. Chanda K, Maiti B, Yellol GS, Chien MH, Kuo ML and Sun CM. Polymer supported synthesis of novel benzoxazole linked benzimidazoles under microwave conditions: in vitro evaluation of VEGFR-3 kinase inhibition activity. Organic & biomolecular chemistry. 2011; 9(6):1917-1926.
14. Salameh A, Galvagni F, Bardelli M, Bussolino F and Oliviero S. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood. 2005; 106(10):3423-3431.
15. Dixelius J, Makinen T, Wirzenius M, Karkkainen MJ, Wernstedt C, Alitalo K and Claesson-Welsh L. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. The Journal of biological chemistry. 2003; 278(42):40973-40979.
16. Min Y, Ghose S, Boelte K, Li J, Yang L and Lin PC. C/EBP-delta regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1alpha. Oncogene. 2011; 30(49):4901-4909.
17. Stanton MJ, Dutta S, Zhang H, Polavaram NS, Leontovich AA, Honscheid P, Sinicrope FA, Tindall DJ, Muders MH and Datta K. Autophagy control by the VEGFC/NRP-2 axis in cancer and its implication for treatment resistance. Cancer research. 2013; 73(1):160-171.
18. Jun Cho H, Kim IK, Park SM, Eun Baek K, Nam IK, Park SH, Ryu KJ, Choi J, Ryu J, Hong SC, Jeong SH, Lee YJ, Ko GH, Won Kim J, Won Lee C and Soo Kang S. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance. International journal of cancer Journal international du cancer. 2014.
19. Muders MH, Zhang H, Wang E, Tindall DJ and Datta K. Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. Cancer research. 2009; 69(15):6042-6048.
20. Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, Wang W, Zhang J and Zhang Y. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways. European journal of cancer. 2011; 47(15):2353-2363.
21. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M and Alitalo K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proceedings of the National Academy of Sciences of the United States of America. 1995; 92(8): 3566-3570.
22. Wu C and Alman BA. Side population cells in human cancers. Cancer letters. 2008; 268(1):1-9.
23. Marotta LL and Polyak K. Cancer stem cells: a model in the making. Current opinion in genetics & development. 2009; 19(1):44-50.
24. Khromova N, Kopnin P, Rybko V and Kopnin BP. Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene. 2012; 31(11):1389-1397.
25. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R and Martin AG. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene. 2012; 31(11):1354-1365.
26. Chou YT, Lee CC, Hsiao SH, Lin SE, Lin SC, Chung CH, Chung CH, Kao YR, Wang YH, Chen CT, Wei YH and Wu CW. The emerging role of SOX2 in cell proliferation and survival and its crosstalk with oncogenic signaling in lung cancer. Stem cells. 2013.
27. Christiansen A and Detmar M. Lymphangiogenesis and cancer. Genes & cancer. 2011; 2(12):1146-1158.
28. Achen MG, Mann GB and Stacker SA. Targeting lymphangiogenesis to prevent tumour metastasis. British journal of cancer. 2006; 94(10):1355-1360.
29. Dean M, Fojo T and Bates S. Tumour stem cells and drug resistance. Nature reviews Cancer. 2005; 5(4):275-284.
30. Shrivastava A, Nunn AD and Tweedle MF. Designer peptides: learning from nature. Current pharmaceutical design. 2009; 15(6):675-681.
31. Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, Wu R and Wu CW. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. American journal of respiratory cell and molecular biology. 1997; 17(3):353-360.
32. Suzuma K, Naruse K, Suzuma I, Takahara N, Ueki K, Aiello LP and King GL. Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. The Journal of biological chemistry. 2000; 275(52):40725-40731.
33. Su JL, Cheng X, Yamaguchi H, Chang YW, Hou CF, Lee DF, Ko HW, Hua KT, Wang YN, Hsiao M, Chen PB, Hsu JM, Bast RC Jr., Hortobagyi GN and Hung MC. FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. Cancer research. 2011; 71(21): 6878-6887.